CompletedPhase 1

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

South Korea20 participantsStarted 2023-11-28

Plain-language summary

To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.

Who can participate

Age range19 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening Exclusion Criteria: \-

What they're measuring

Number of occurrences for grade 3 or higher adverse drug reactions (ADRs) according to CTCAE 5.0

Timeframe: At 4, 8, 12 week after the injection

Trial details

NCT IDNCT06212960

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-02-26

View on ClinicalTrials.gov More Glabellar Lines trials